干扰素α1b雾化吸入治疗小儿上呼吸道病毒性感染的临床研究

Clinical Research of Treating Viral Infection of Upper Respiratory Tract in Children with Interferon Alpha 1b Atomized Inspiring

目的:临床观察和评估干扰素α1b雾化吸入治疗儿童上呼吸道病毒性感染的临床疗效及安全性。方法:采用随机、开放、平行对照方法,163例临床诊断为病毒性上呼吸道感染患儿,分为实验组83例,对照组80例,两组病例治疗前性别、年龄、身高、临床症状等差异无显著性;试验组干扰素α1b雾化吸入治疗,每次生理盐水20mL加干扰素α1b 20万单位,一日两次,对照组生理盐水20mL雾化吸入,每日两次。结果:实验组在退热、感冒症状改善方面与对照组比较,病程缩短,差异有显著性。结论:干扰素α1b雾化吸入疗效确切,药物直达口咽,起效迅速,不良反应小,可作为早期干预上呼吸道病毒感染的首选用药。

Objective： To evaluate the efficacy and safety of nebulized IFN-otlb on viral infection of upper respiratory tract in children. Method： A randomized, open lable, parallel, controlled trial was per-formed. 163 children with viral upper respiratory tract infection were randomly allocated to experiment group （n = 83 ） and control group （n=80）. There were no αlt/erenees on genaer, age, height, festation of patients between two groups. Experiment group used interferon-1 alpha, control group used NS. Result： Experiment group compared with control group, There were fine effect in the aspects of pyretolysis and cold improving. There＇s significant difference between two groups. Conclusion： Interferon-lalpha could be effectively and safety for respiratory virus infection of upper respiratory tract in children, and could easily reach oropharynx in high concentration and fewer adverse effects. A conception of treating common cold using interferon-lalpha aerosol without injection as a first choice are proposed.